Arcturus Therapeutics Holdings (ARCT) Other Operating Expenses (2024 - 2026)

Arcturus Therapeutics Holdings' Other Operating Expenses history runs 3 years deep, the most recent figure standing at -$33.0 million for Q1 2026.

• Quarterly Other Operating Expenses changed N/A year-over-year to -$33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$110.4 million (down 186.09% YoY) and the FY2025 annual result came in at -$168.8 million, changed N/A from the prior year.
• Other Operating Expenses was -$33.0 million for Q1 2026 at Arcturus Therapeutics Holdings, up from -$40.7 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $203.2 million in Q4 2024 and bottomed at -$74.9 million in Q2 2024.
• A 3-year average of $3.6 million and a median of -$36.7 million in 2025 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 120.05% in 2025, while the deepest fall reached 120.05% in 2025.
• Arcturus Therapeutics Holdings' Other Operating Expenses stood at $203.2 million in 2024, then sank by 120.05% to -$40.7 million in 2025, then climbed by 19.08% to -$33.0 million in 2026.
• Business Quant data shows ARCT's Other Operating Expenses at -$33.0 million in Q1 2026, -$40.7 million in Q4 2025, and -$36.7 million in Q3 2025.